Based on this, we plan to use computer-assisted drug design technology to develop an agonist of ERα, which can effectively reduce lipid accumulation by targeting ERα, thereby achieving the purpose of alleviating NAFLD. Here, ESR1 is linked to metabolic dysfunction-associated steatotic liver disease.